TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant ...

Tvardi Therapeutics Inc. TVRD on Wednesday reported Phase 1 results for TTI-109, its next-generation STAT3 inhibitor.

A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.

RLTs were a hot topic at ASCO 2026, but experts note that certain limitations must be addressed to facilitate their ...

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 inhibitor in heavily pretreated, largely refractory mantle cell lymphoma. At ASH ...

A 74-year-old man with an active lifestyle and no family history of prostate cancer presented with mild urinary hesitancy and ...

Two tocilizumab biosimilars had similar safety, tolerability, and immunogenicity compared with the reference biologic, according to abstracts presented at the American College of Rheumatology (ACR) ...

A study published in the Journal of Cannabis Research assessed the safety and tolerability of cannabidiol (CBD) and alcohol ...

A phase 3 trial suggests AD109 could offer a long-sought oral option for obstructive sleep apnea, improving breathing and oxygenation during sleep, but side effects and early discontinuation may limit ...

Misako Nagasaka, MD, PhD, describes the tolerability results with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced non–small cell lung cancer from ...

PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal treatment-related events, and low rates of rash and ...